HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons
Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články, přehledy
PubMed
35336889
PubMed Central
PMC8952509
DOI
10.3390/v14030482
PII: v14030482
Knihovny.cz E-zdroje
- Klíčová slova
- HCV, WHO, epidemiology, hepatitis, screening, therapy,
- MeSH
- COVID-19 * epidemiologie prevence a kontrola MeSH
- hepatitida C * diagnóza epidemiologie prevence a kontrola MeSH
- lidé MeSH
- pandemie prevence a kontrola MeSH
- věznice MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
In 2016, the WHO announced a plan to eliminate viral hepatitis as a public health threat by 2030. In this narrative review, experts from Bulgaria, Croatia, the Czech Republic, Hungary, Latvia, Lithuania, Poland and Slovakia assessed the feasibility of achieving the WHO 2030 target for HCV infections in Central Europe. They focused mainly on HCV micro-elimination in prisons, where the highest incidence of HCV infections is usually observed, and the impact of the COVID-19 pandemic on the detection and treatment of HCV infections. According to the presented estimates, almost 400,000 people remain infected with HCV in the analyzed countries. Interferon-free therapies are available ad libitum, but the number of patients treated annually in the last two years has halved compared to 2017-2019, mainly due to the COVID-19 pandemic. None of the countries analyzed had implemented a national HCV screening program or a prison screening program. The main reason is a lack of will at governmental and prison levels. None of the countries analyzed see any chance of meeting the WHO targets for removing viral hepatitis from the public threat list by 2030, unless barriers such as a lack of political will and a lack of screening programs are removed quickly.
1st Department of Internal Medicine University of Pécs H7624 Pécs Hungary
Department of Gastroenterolgy Somogy Megyei Kaposi Mór Oktató Kórház H7400 Kaposvár Hungary
Department of Gastroenterology Lithuanian University of Health Sciences LT50061 Kaunas Lithuania
Department of Infectious Diseases Jan Kochanowski University 25 317 Kielce Poland
Zobrazit více v PubMed
World Health Organization Global Hepatitis Report 2017; Geneva, Switzerland. World Health Organization; 2017. [(accessed on 26 December 2021)]. Available online: https://apps.who.int/iris/handle/10665/255016.
Marshall A.D., Cunningham E.B., Nielsen S., Aghemo A., Alho H., Backmund M., Bruggmann P., Dalgard O., Seguin-Devaux C., Flisiak R., et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol. Hepatol. 2018;3:125–133. doi: 10.1016/S2468-1253(17)30284-4. PubMed DOI
Cooke G.S., Andrieux-Meyer I., Applegate T.L., Atun R., Burry J.R., Cheinquer H., Dusheiko G., Feld J.J., Gore C., Griswold M.G., et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 2019;4:135–184. PubMed
Flisiak R., Zarębska-Michaluk D., Janczewska E., Łapiński T., Rogalska M., Karpińska E., Mikuła T., Bolewska B., Białkowska J., Flejscher-Stępniewska K., et al. Five-year follow-up of cured HCV patients under real-world interferon-free therapy. Cancers. 2021;13:3694. doi: 10.3390/cancers13153694. PubMed DOI PMC
World Health Organization Global Health Sector Strategy on Viral Hepatitis 2016–2021. Towards Ending Viral Hepatitis; Geneva, Switzerland. World Health Organization; 2016. [(accessed on 26 December 2021)]. Available online: https://apps.who.int/iris/handle/10665/246177.
Flisiak R., Frankova S., Grgurevic I., Hunyady B., Jarcuska P., Kupčinskas L., Makara M., Simonova M., Sperl J., Tolmane I., et al. How close are we to hepatitis C virus elimination in Central Europe? Clin. Exp. Hepatol. 2020;6:1–8. doi: 10.5114/ceh.2020.93049. PubMed DOI PMC
Flisiak R., Zarębska-Michaluk D., Frankova S., Grgurevic I., Hunyady B., Jarcuska P., Kupčinskas L., Makara M., Simonova M., Sperl J., et al. Is elimination of HCV in 2030 realistic in Central Europe. Liver Int. 2021;41((Suppl. S1)):56–60. doi: 10.1111/liv.14834. PubMed DOI
Blach S., Kondili L.A., Aghemo A., Cai Z., Dugan E., Estes C., Gamkrelidze I., Ma S., Pawlotsky J.M., Razavi-Shearer D., et al. Impact of COVID-19 on global HCV elimination efforts. J. Hepatol. 2021;74:31–36. doi: 10.1016/j.jhep.2020.07.042. PubMed DOI PMC
Gamkrelidze I., Pawlotsky J.M., Lazarus J.V., Feld J.J., Zeuzem S., Bao Y., Gabriela Pires Dos Santos A., Sanchez Gonzalez Y., Razavi H. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021;41:456–463. doi: 10.1111/liv.14779. PubMed DOI
Petrunov B., Kojauharova M., Teoharov P., Haidushka I., Sotirova P., Sredkova M., Russev I., Zacharakis G., Tzara F., Vafeiadis N., et al. EU project interreg II: Seroepidemiology study on hepatitis C and B viral infections prevalence in Bulgaria and nothern Greece. J. Hepatol. 2002;36((Suppl. S1)):138–139. doi: 10.1016/S0168-8278(02)80497-4. PubMed DOI
National Focus Center (NFC) on Drugs and Addiction. Annual National Report on the Problems of Drugs and Drug Use in Bulgaria, 2018. [(accessed on 26 December 2021)]. Available online: http://anketi.info/images/folder/ar_2018.pdf.
Varleva T., Boneva S., Naseva E. Report on Integrated Biological and Behavioral Supervision on HIV among Sex-Workers, Men and Women in the Period 2004–2012. 1st ed. Bulgarian Ministry of Health; Bulgaria, Sofia: 2015. pp. 1–41.
Varleva T., Kabakchieva E., Naseva E. Report on Integrated Biological and Behavioral Supervision on HIV among 18–15 Years Old Men in Roma-Community, in the Period 2005–2012. 1st ed. Bulgarian Ministry of Health; Bulgaria, Sofia: 2015. pp. 1–41.
Varleva T., Georgieva V., Naseva E. Report on Integrated Biological and Behavioral Supervision on HIV among Prisoners in the Period 2006–2011. 1st ed. Bulgarian Ministry of Health; Bulgaria, Sofia: 2015. pp. 1–41.
Croatian Institute of Public Health: Report on Persons Treated for Drug Abuse in Croatia in 2019. [(accessed on 5 December 2021)]. Available online: https://www.hzjz.hr/wp-content/uploads/2020/10/Ovisni_2019-1.pdf.
Papic N., Radmanic L., Dusek D., Kurelac I., Zidovec Lepej S., Vince A. Trends of Late Presentation to Care in Patients with Chronic Hepatitis C during a 10-Year Period in Croatia. Infect. Dis. Rep. 2020;12:74–81. doi: 10.3390/idr12030016. PubMed DOI PMC
Croatian Institute of Public Health: Infectious Diseases Registry. [(accessed on 5 December 2021)]. Available online: https://www.hzjz.hr/sluzba-epidemiologija-zarazne-bolesti/odjel-za-pracenje-zaraznih-bolesti.
Fraňková S., Urbánek P., Husa P., Němeček V., Razavi H., Razavi-Shearer D., Chlíbek R., Šperl J. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden. Cent. Eur. J. Public Health. 2019;27:93–98. doi: 10.21101/cejph.a5350. PubMed DOI
Frankova S., Jandova Z., Jinochova G., Kreidlova M., Merta D., Sperl J. Therapy of chronic hepatitis C in people who inject drugs: Focus on adherence. Harm. Reduct. J. 2021;18:69. doi: 10.1186/s12954-021-00519-y. PubMed DOI PMC
Mravčík V., Chomynová P., Grohmannová K., Janíková B., Černíková T., Fidesová H. Drug Situation in the Czech Republic in 2019. Office of the Government of the Czech Republic; Prague, Czech Republic: 2019. [(accessed on 26 December 2021)]. Available online: https://www.drogy-info.cz/en/publications/annual-reports/drug-situation-in-the-czech-republic-in-2019/
The National Institute of Public Health of the Czech Republic. [(accessed on 23 December 2021)]. Available online: http://www.szu.cz/uploads/documents/szu/infekce/2021/tabulka_leden_rijen_2021.pdf.
Barna T.K., Ozsvár Z.S., Szendrényi V. Prevalence of hepatitis C antibody in Hungarian blood donors. Orv. Hetil. 1996;137:507–511. PubMed
Országos Epidemiológiai Központ HIV- and HCV prevalence amongst intravenous drug users in Hungary, 2014. EPINFO. 2015;22:189–194.
Gervain J. Analysis of hepatitis C virus type and subtype distribution in Hungary. Orv. Hetil. 2018;159((Suppl. S2)):2–8. doi: 10.1556/650.2018.31177. PubMed DOI
Latvian Center of Disease Prevention and Control Health Statistics Database 2021. [(accessed on 19 January 2022)]; Available online: https://statistika.spkc.gov.lv/pxweb/en/Health/
Liakina V., Hamid S., Tanaka J., Olafsson S., Sharara A.I., Alavian S.M., Gheorghe L., El Hassan E.S., Abaalkhail F., Abbas Z., et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—Volume 3. J. Viral Hepat. 2015;22((Suppl. S4)):4–20. doi: 10.1111/jvh.12475. PubMed DOI
Kupcinskas L. ((Lithuanian University of Health Sciences, Kaunas, Lithuania)). Personal communication. 2021.
Grubyte V., Urboniene J., Nedzinskiene L., Jancoriene L. The Epidemiological Patterns of Hepatitis C in Lithuania: Changes in Surveillance from 2005 to 2018. Medicina. 2021;57:1120. doi: 10.3390/medicina57101120. PubMed DOI PMC
Čiupkevičienė E., Šumskienė J., Kupčinskas L. Characteristics of patients with hepatitis C and distribution of viral genotypes in Lithuania. Abstracts accepted for the International Scientific Conference on Medicine organized within the frame of the 79th International Scientific Conference of the University of Latvia. Medicina. 2021;57((Suppl. S1)):196. PubMed
Piekarska A., Tomasiewicz K., Halota W., Jaroszewicz J., Krygier R., Małkowski P., Pawłowska M., Simon K., Tronina O., Zarębska-Michaluk D., et al. Searching for the optimal population for hepatitis C virus screening in Poland. Clin. Exp. Hepatol. 2020;6:74–76. doi: 10.5114/ceh.2020.94969. PubMed DOI PMC
Flisiak R., Zarębska-Michaluk D. Perspectives of hepatitis C virus (HCV) elimination in Poland. Clin. Exp. Hepatol. 2019;5:210–214. doi: 10.5114/ceh.2019.87633. PubMed DOI PMC
Flisiak R., Zarębska-Michaluk D., Jaroszewicz J., Lorenc B., Klapaczyński J., Tudrujek-Zdunek M., Sitko M., Mazur W., Janczewska E., Pabjan P., et al. Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection. Pol. Arch. Intern. Med. 2020;130:163–172. doi: 10.20452/pamw.15181. PubMed DOI
Public Health Authority of the Slovak Republic Immunological Survey in the Slovak Republic in 2018 (Seroprevalence Study) [(accessed on 23 December 2021)]. Available online: https://www.uvzsr.sk/docs/info/ip/IP2018_Zaverecna_sprava.pdf.
HEPIO Project Investigators Short Report: The current situation in the occurrence of chronic viral hepatitis C in Slovakia. Trendy Hepatol. 2018;10:50–55.
Hunyady B., Gerlei Z.S., Gervain J. Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 23 September 2020. Cent. Eur. J. Gastroenterol. Hepatol. 2021;7:40–54.
Jancoriene L., Polubenko K., Kazenaite E., Buivydiene A., Jakutiene J., Tolmane I., Jeruma A., Radzisauskiene D., Mockiene E., Ambrozaitis A. Direct-acting antivirals ombitasvir/paritaprevir/ritonavir + dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis: Real-life experience in Lithuania and Latvia. Hepat. Mon. 2018;18:e62105.
Tolmane I., Rozentale B., Arutjunana S., Jeruma A., Kuse V., Simanis R. Original versus generic direct acting antivirals in treatment of chronic hepatitis C patients: Real life data from Latvia. Open Infect. Dis. J. 2018;10:63–70. doi: 10.2174/1874279301810010063. DOI
Flisiak R., Zarębska-Michaluk D., Janczewska E., Staniaszek A., Gietka A., Mazur W., Tudrujek M., Tomasiewicz K., Belica-Wdowik T., Baka-Ćwierz B., et al. Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study. J. Viral Hepat. 2018;25:661–669. doi: 10.1111/jvh.12861. PubMed DOI
Ministry of Health of the Slovak Republic List of Categorized Drugs 1 December 2021–31 December 2021. Part B: Indicative Restrictions. [(accessed on 23 December 2021)]; Available online: https://www.health.gov.sk/Clanok?lieky202112.
State Insitute for Drug Control of the Czech Republic. [(accessed on 23 December 2021)]. Available online: https://opendata.sukl.cz/?q=katalog/dis-13.
Makara M., Schaff Z.S. Practical Issues of Hepatitis C Screening in Healthcare Worker Population. [(accessed on 20 December 2021)]. Available online: https://mok.hu/hirek/szakmai/az-egeszsegugyi-dolgozok-hepatitis-c-szuresenek-gyakorlati-vonatkozasai.
Vilibic-Cavlek T., Kucinar J., Kaic B., Vilibic M., Pandak N., Barbic L., Stevanovic V., Vranes J. Epidemiology of hepatitis C in Croatia in the European context. World J. Gastroenterol. 2015;21:9476–9493. doi: 10.3748/wjg.v21.i32.9476. PubMed DOI PMC
HUHIV NGO: Širenje Mreže Socijelnih Usluga u Zajednici-Faza 1: Deinstitucionalizacija Usluga za Osobe s Problemima Ovisnosti UP.02.2.2.06.0373. [(accessed on 5 December 2021)]. Available online: https://www.huhiv.hr/inkluzijom-ranjivih-skupina-do-socijalne-pravde/EU.
Moazen B., Dolan K., Moghaddam S.S., Lotfizadeh M., Duke K., Neuhann F., Stöver H., Jahn A. Availability, Accessibility, and Coverage of Needle and Syringe Programs in Prisons in the European Union. Epidemiol. Rev. 2020;42:19–26. doi: 10.1093/epirev/mxaa003. PubMed DOI
Vince A., Dugan E., Nemeth-Blažić T., Filipec T., Hrstic I., Lukšić B., Nonkovic D., Reic T., Coleman S., Blach S. Strategies to eliminate hepatitis C in Croatia, a modelling study. Liječ. Vjesnik. 2020;142:285–295.
